Government-Owned Inventions; Availability for Licensing, 43392-43393 [2017-19590]
Download as PDF
<![CDATA[
43392
Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices
When
submitting comments or requesting
information, please include the
information request collection title for
reference, in compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995.
Information Collection Request Title:
Poison Help General Population Survey
OMB Number 0915–0343,
Reinstatement.
Abstract: HRSA is requesting
approval by OMB for reinstatement with
change of a previously approved
collection of information (OMB control
number 0915–0343). Annually, poison
control centers (PCCs) in the U.S.
manage approximately 2.8 million calls,
providing ready and direct access to
vital public health emergency
information and response. In 2001, the
Poison Help line, a single, national tollfree phone number (800–222–1222) was
established to ensure universal access to
PCC services, 24 hours a day, 7 days a
week. The Poison Help campaign is the
only national media effort to promote
SUPPLEMENTARY INFORMATION:
awareness and use of the national tollfree phone number.
The Poison Help campaign aims to
reach a wide audience, as individuals of
all ages are at risk for poisoning and
may need to access PCC services. The
‘‘Poison Help General Population
Survey’’ is a 10-minute telephone
survey designed to assess the
campaign’s impact among 2,000
households in the United States. The
survey is conducted with an adult
household member and addresses topics
related to the types of individuals or
organizations to contact for information,
advice, and treatment related to a
poisoning.
Need and Proposed Use of the
Information: Survey results will be used
to guide future communication,
education, and outreach efforts and will
allow the tracking of longitudinal data
from near-identical prior surveys
conducted in 2008 and 2011. The
survey has been updated to include
questions regarding one of the Secretary
of HHS’ priority areas, addressing the
opioid crisis, and to definitively
ascertain respondents’ knowledge of the
Poison Help Line and phone usage.
Likely Respondents: This study
includes two respondent groups,
individuals and households with an
adult member 18 years and older.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Instrument
Responses per
respondent
Total
responses
Hours per
response
Total burden
hours
Survey Respondents ........................................................
Screened households ......................................................
2000
2600
1
1
2000
2600
.166
.016
332
41.6
Total ..........................................................................
4600
............................
4600
........................
374
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by emailing the indicated
licensing contact at the National Heart,
Lung, and Blood, Office of Technology
Transfer and Development Office of
Technology Transfer, 31 Center Drive,
Room 4A29, MSC2479, Bethesda, MD
20892–2479; telephone: 301–402–5579.
A signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
[FR Doc. 2017–19608 Filed 9–14–17; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
ACTION:
Notice.
Government owned
intellectual property covering imaging
agents with improved renal clearance
available for licensing and
commercialization.
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:07 Sep 14, 2017
Jkt 241001
The
inventions listed below are owned by an
agency of the U.S. Government and are
available for licensing in the U.S. in
accordance with 35 U.S.C. 209 and 37
CFR part 404 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
SUPPLEMENTARY INFORMATION:
National Institutes of Health,
HHS.
PO 00000
Frm 00068
Fmt 4703
Sfmt 4725
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing. A description of the
technology available for licensing
follows.
Methods of Using Inhibitors To
Enhance Therapeutic Uses of
Endocannabinoids
Description of Technology: The
invention pertains to methods of using
compounds that inhibit fatty acid amide
hydrolase (FAAH) enzymes that are
responsible for the degradation of
oleamide and anandamide. Inhibition of
degradation can be used as treatment
modality for hypertension and for sleep
disorders. The issued patent lists
potentially useful compounds, one such
useful compound in particular is
E:\FR\FM\15SEN1.SGM
15SEN1
EN15SE.001</GPH>
Amy McNulty.
Acting Director, Division of the Executive
Secretariat.
Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices
Potential Commercial Applications:
• Therapeutics for hypertension
• Therapeutics for anxiety disorders
• Therapeutics for sleep disorders
Development Stage:
• In vivo data available
Inventors: George Kunos and
Alexandros Makriyannis (both of
NIAAA)
Intellectual Property: HHS Reference
No. E–211–2006/0–US–06.
• U.S. Patent 8,293,724 filed April 6,
2010, issued October 23, 2012.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@nih.gov.
Collaborative Research Opportunity:
The National Institute of Environmental
Health Sciences seeks statements of
capability or interest from parties
interested in collaborative research to
further develop and evaluate, please
contact Peg Koelble, Office of
Technology Transfer, National Heart,
Lung and Blood Institute, koelblep@
nhlbi.nih.gov, 301–594–4095.
Dated: September 7, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2017–19590 Filed 9–14–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Chris Kornak, 240–627–3705, chris.
kornak@nih.gov. Licensing information
and copies of the U.S. patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office (TTIPO), 5601 Fishers
Lane, Suite 6D, MSC 9804, Rockville,
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:07 Sep 14, 2017
Jkt 241001
43393
No. PCT/US2017/021573 filed on 03/09/
2017.
Licensing Contact: Chris Kornak, 240–
627–3705, chris.kornak@nih.gov.
Collaborative Research Opportunity:
The Technology Transfer and
Intellectual Property Office (TTIPO) is
seeking parties interested in
Recombinant HIV-1 Envelope Proteins
collaborative research to further develop
and Their Use
the technology. In particular, NIAID is
Description of Technology: Millions of interested in partnerships utilizing
vector vaccine platforms for expressing
people are infected with HIV-1
these immunogens.
worldwide. In the U.S., there are about
However, NIAID is willing to discuss
30,000 new cases of HIV infection
other applications of this technology.
reported annually. Currently, there are
For collaboration opportunities, please
effective, anti-retroviral therapeutics
contact Chris Kornak, 240–627–3705,
available to treat or prevent HIV
chris.kornak@nih.gov.
infection. However, available antiretroviral therapeutics require life-long
Dated: September 7, 2017.
administration.
Suzanne Frisbie,
During infection, proteases of the host Deputy Director, Technology Transfer and
cell cleave gp160 into gp120 and gp41.
Intellectual Property Office, National Institute
Gp41 is an integral membrane protein,
of Allergy and Infectious Diseases.
while gp120 protrudes from the mature
[FR Doc. 2017–19591 Filed 9–14–17; 8:45 am]
virus. Together gp120 and gp41
BILLING CODE 4140–01–P
aggregate as trimers that make up the
HIV-1 envelope (‘‘Env’’) spike, which is
a target for neutralizing antibodies.
DEPARTMENT OF HEALTH AND
NIAID researchers have constructed a HUMAN SERVICES
recombinant HIV-1 trimer immunogen.
National Institutes of Health
In particular, the recombinant gp120
protein in the trimer is stabilized in a
closed conformation, preventing it from National Institute on Deafness and
Other Communication Disorders;
binding to CD4. The advantage of the
Notice of Closed Meetings
closed conformation is that it can
stabilize the epitopes that bind to
Pursuant to section 10(d) of the
broadly neutralizing antibodies,
Federal Advisory Committee Act, as
minimize the binding of gp120 with
amended, notice is hereby given of the
weakly or non-neutralizing antibodies,
following meetings.
and prevent conformational changes
The meetings will be closed to the
induced by CD4 as well as immunogen
public in accordance with the
sequestration by CD4 in vivo. Research
provisions set forth in sections
has also indicated that recombinant Env 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
ectodomain trimers can induce higher
as amended. The grant applications and
neutralizing antibody titers than wild
the discussions could disclose
type Env trimers in animal models.
confidential trade secrets or commercial
This technology is available for
property such as patentable material,
licensing for commercial development
and personal information concerning
in accordance with 35 U.S.C. 209 and 37 individuals associated with the grant
CFR part 404, as well as for further
applications, the disclosure of which
development and evaluation under a
would constitute a clearly unwarranted
research collaboration.
invasion of personal privacy.
Potential Commercial Applications:
Name of Committee: National Institute on
• HIV-1 immunogen
Deafness and Other Communication
• New methods for isolating broadly
Disorders Special Emphasis Panel; Chemical
neutralizing antibodies
Senses Fellowship Review.
Competitive Advantages:
Date: October 11, 2017.
• A new strategy in inducing immune
Time: 12:30 p.m. to 3:00 p.m.
response against HIV-1
Agenda: To review and evaluate grant
applications.
Development Stage:
Place: National Institutes of Health.
• Pre-Clinical; Proof-of-concept
Neuroscience Center, 6001 Executive
studies in nonhuman primate
Boulevard, Rockville, MD 20852 (Telephone
models
Conference Call).
Inventors:
Contact Person: Sheo Singh, Ph.D.,
Paolo Lusso, NIAID, NIH
Scientific Review Officer, Scientific Review
Peng Zhang, NIAID, NIH
Branch, Division of Extramural Activities,
Publications: Pending.
6001 Executive Blvd., Room 8351, Bethesda,
Intellectual Property: HHS Reference
MD 20892, 301–496–8683, singhs@
No. E–102–2016/0—PCT Application
nidcd.nih.gov.
MD 20892, tel: 301–496–2644, fax: 240–
627–3117. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
E:\FR\FM\15SEN1.SGM
15SEN1
]]>Agencies
[Federal Register Volume 82, Number 178 (Friday, September 15, 2017)]
[Notices]
[Pages 43392-43393]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19590]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Government owned intellectual property covering imaging agents
with improved renal clearance available for licensing and
commercialization.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by emailing the
indicated licensing contact at the National Heart, Lung, and Blood,
Office of Technology Transfer and Development Office of Technology
Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD 20892-2479;
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may
be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: The inventions listed below are owned by an
agency of the U.S. Government and are available for licensing in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing. A description of the technology available for
licensing follows.
Methods of Using Inhibitors To Enhance Therapeutic Uses of
Endocannabinoids
Description of Technology: The invention pertains to methods of
using compounds that inhibit fatty acid amide hydrolase (FAAH) enzymes
that are responsible for the degradation of oleamide and anandamide.
Inhibition of degradation can be used as treatment modality for
hypertension and for sleep disorders. The issued patent lists
potentially useful compounds, one such useful compound in particular is
[GRAPHIC] [TIFF OMITTED] TN15SE.001
[[Page 43393]]
Potential Commercial Applications:
Therapeutics for hypertension
Therapeutics for anxiety disorders
Therapeutics for sleep disorders
Development Stage:
In vivo data available
Inventors: George Kunos and Alexandros Makriyannis (both of NIAAA)
Intellectual Property: HHS Reference No. E-211-2006/0-US-06.
U.S. Patent 8,293,724 filed April 6, 2010, issued October
23, 2012.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
shmilovm@nih.gov.
Collaborative Research Opportunity: The National Institute of
Environmental Health Sciences seeks statements of capability or
interest from parties interested in collaborative research to further
develop and evaluate, please contact Peg Koelble, Office of Technology
Transfer, National Heart, Lung and Blood Institute,
koelblep@nhlbi.nih.gov, 301-594-4095.
Dated: September 7, 2017.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2017-19590 Filed 9-14-17; 8:45 am]
BILLING CODE 4140-01-P
